PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE

Authors

  • Zeeshan Ali Department of Medicine, Jinnah Postgraduate Medical Center, Karachi-Pakistan
  • Mariam Riaz Department of Medicine, Jinnah Postgraduate Medical Center, Karachi-Pakistan
  • Altaf Alam Evercare Hospital Lahore-Pakistan
  • Javed Iqbal Faroqi Al-Hayat Clinic Peshawar-Pakistan

DOI:

https://doi.org/10.55519/JAMC-04-12433

Keywords:

NAFLD, Fatty Liver, Diabetes, NASH, MASH, MASLD, ALD, MetALD, Steatotic Liver Disease, SLD

Abstract

The Nomenclature of diseases intends to have a system whereby diagnosis can be suitably catalogued without ambiguity or confusion. Therefore, the nomenclature of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), is ambiguous owing to perplexity in terms of aetiology and possible stigmatizing language. To address these concerns, there is an apparent need for change in the current nomenclature.

Author Biography

Zeeshan Ali, Department of Medicine, Jinnah Postgraduate Medical Center, Karachi-Pakistan

Associate Professor of Medicine Jinnah Sindh Medical University & JPMC Karachi Medical Unit III, Ward-7 JPMC Karachi

References

Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches: Pathogenesis and therapy of NASH. J Gastroenterol Hepatol 2013;28:68–76.

Imajo K, Yoneda M, Kessoku T, Ogawa Y, Maeda S, Sumida Y, et al. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci 2013;14(11):21833–57.

Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 2019;103(1):e1–13.

Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, et al. Cardiovascular risk of isolated systolic or diastolic hypertension in young adults. Circulation 2020;141(22):1778–86.

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management, and effects of weight loss. BMC Endocr Disord 2022;22(1):63.

Carol M, Pérez-Guasch M, Solà E, Cervera M, Martínez S, Juanola A, et al. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One 2022;17(4):e0265153.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73(1):202–9.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7(5):388–90.

Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology 2021;73(3):1194–8.

Ng CH, Chan KE, Muthiah M, Tan C, Tay P, Lim WH, et al. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology 2023;77(5):1712–21.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;S0168-8278(23):00418.

Downloads

Published

2023-10-10